Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ampio Pharmaceuticals Inc AMPE

Healthcare
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Recent & Breaking News (OTCPK:AMPE)

Wall Street Fundamentals Releases New In-Depth Stock Reports on AMPE, CRME, OPXA and PCYC

Accesswire September 27, 2013

Ampio Pharmaceuticals, Inc. Announces $25 Million Financing

PR Newswire September 26, 2013

Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial

PR Newswire August 14, 2013

Luoxis Diagnostics, Inc. announces positive results from first clinical study conducted with company's proprietary diagnostic platform

PR Newswire June 20, 2013

Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog

PR Newswire June 7, 2013

Ampio Pharmaceuticals to List on the NYSE MKT

PR Newswire June 6, 2013

Ampio Pharmaceuticals Provides Clinical Updates

PR Newswire June 3, 2013

Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference

PR Newswire May 13, 2013

Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee

PR Newswire April 25, 2013

Free Research Reports on AEZS, AMPE, ELN and MDCO Issued by the Bedford Report

Marketwired March 12, 2013

Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane(TM)

PR Newswire March 11, 2013

LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals

Marketwired March 7, 2013

Ampio Pharmaceuticals Initiates Clinical Trial of Optina(TM) in Diabetic Macular Edema (DME): First Patient Dosed

PR Newswire February 27, 2013

Ampio Pharmaceuticals Modifies Ampion(TM) IND for Osteoarthritis of the Knee to Include A Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial

PR Newswire February 25, 2013

Ampio forms Luoxis Diagnostics to Commercialize ORP Technology

PR Newswire February 11, 2013

Ampio Pharmaceuticals Announces Active IND for Optina(tm) for the Treatment of Diabetic Macular Edema (DME)

PR Newswire January 22, 2013

Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference

PR Newswire January 22, 2013